冠心病患者中CYP2C19基因多态性与氯吡格雷抵抗及预后相关性研究进展

氯吡格雷是一种临床疗效良好的抗血小板药物,能够显著降低冠心病患者特别是血管支架术后患者的主要不良心血管事件的风险,然而在实际临床应用过程中,部分患者却存在着不同程度的氯吡格雷抵抗现象。氯吡格雷抵抗受多种因素影响,而CYP2C19基因多态性是其最重要的内部因素,合并用药是其主要临床因素之一。该研究对冠心病患者在介入治疗后服用氯吡格雷或合并质子泵抑制剂用药后,发生不良预后是否与CYP2C19基因多态性相关的研究现状进行综述,旨在对氯吡格雷在临床个体化给药方案提供一定的相关参考依据。

Research progress in the correlation between CYP2C19 gene polymorphism and clopidogrel resistance and prognosis in patients with coronary heart disease

Clopidogrel is an effectively-prescribed antiplatelet medication,which can reduce the risk of major adverse cardiovascular event in coronary heart disease patients especially those undergoing percutaneous coronary intervention.However some sufferers had clopidogrel resistance.Researches suggest that clopidogrel resistance is influenced by many factors,CYP2C19 gene polymorphism being the most important internal factors and drug combination one of the major clinical factors.While studying coronary heart disease patients taking clopidogrel or merging of proton pump inhibitors after interventional therapy,we review the relationship between poor prognosis and CYP2C19 gene polymorphisms.After this discussion,the guiding reference is used for individualized drug administration.